RU2011128013A - Композиции ингибиторов тирозинкиназных рецепторов белков - Google Patents
Композиции ингибиторов тирозинкиназных рецепторов белков Download PDFInfo
- Publication number
- RU2011128013A RU2011128013A RU2011128013/04A RU2011128013A RU2011128013A RU 2011128013 A RU2011128013 A RU 2011128013A RU 2011128013/04 A RU2011128013/04 A RU 2011128013/04A RU 2011128013 A RU2011128013 A RU 2011128013A RU 2011128013 A RU2011128013 A RU 2011128013A
- Authority
- RU
- Russia
- Prior art keywords
- oxo
- dihydro
- propyl
- methyl
- carboxamide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- -1 -CONRR Chemical group 0.000 claims abstract 22
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 19
- 150000003839 salts Chemical class 0.000 claims abstract 19
- 239000012453 solvate Substances 0.000 claims abstract 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 17
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 11
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 11
- 125000002252 acyl group Chemical group 0.000 claims abstract 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 10
- 125000003118 aryl group Chemical group 0.000 claims abstract 10
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims abstract 10
- 150000002431 hydrogen Chemical group 0.000 claims abstract 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 10
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract 7
- 125000004429 atom Chemical group 0.000 claims abstract 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract 5
- 150000002367 halogens Chemical class 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 26
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 4
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 101150111783 NTRK1 gene Proteins 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 230000003444 anaesthetic effect Effects 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 201000009032 substance abuse Diseases 0.000 claims 3
- 231100000736 substance abuse Toxicity 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 229940121954 Opioid receptor agonist Drugs 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 230000001773 anti-convulsant effect Effects 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 229940125717 barbiturate Drugs 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 150000001557 benzodiazepines Chemical class 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 2
- 239000003589 local anesthetic agent Substances 0.000 claims 2
- 239000003176 neuroleptic agent Substances 0.000 claims 2
- 230000000701 neuroleptic effect Effects 0.000 claims 2
- 239000002858 neurotransmitter agent Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000003402 opiate agonist Substances 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 239000010802 sludge Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- XPPBCXSMFHFWEJ-JGCGQSQUSA-N (12ar)-n-[2-(4-benzylpiperidin-1-yl)ethyl]-5-[(3-fluorophenyl)methyl]-6-oxo-7,9,10,11,12,12a-hexahydropyrido[1,2-d][1,4]benzodiazepine-3-carboxamide Chemical compound FC1=CC=CC(CN2C(CN3CCCC[C@@H]3C3=CC=C(C=C32)C(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=O)=C1 XPPBCXSMFHFWEJ-JGCGQSQUSA-N 0.000 claims 1
- JNVLDPFCQWJRQK-NJZRLIGZSA-N (2e)-2-[(4-ethoxy-3-methoxyphenyl)methylidene]-n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-4-methyl-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=C(OC)C(OCC)=CC=C1\C=C\1C(=O)N(C)C2=CC(C(=O)NCCCN3CCN(CC3)C=3C(=CC=CC=3)F)=CC=C2S/1 JNVLDPFCQWJRQK-NJZRLIGZSA-N 0.000 claims 1
- GIUUODWOUQNAER-XHLNEMQHSA-N (2e)-n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-2-[(2-methoxyphenyl)methylidene]-4-methyl-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound COC1=CC=CC=C1\C=C\1C(=O)N(C)C2=CC(C(=O)NCCCN3CCN(CC3)C=3C(=CC=CC=3)F)=CC=C2S/1 GIUUODWOUQNAER-XHLNEMQHSA-N 0.000 claims 1
- TUNCBIPYIJLOFJ-BWAHOGKJSA-N (2z)-2-benzylidene-3-oxo-n-[3-(2-propylpiperidin-1-yl)propyl]-4h-1,4-benzothiazine-6-carboxamide Chemical compound CCCC1CCCCN1CCCNC(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 TUNCBIPYIJLOFJ-BWAHOGKJSA-N 0.000 claims 1
- CKDUDHCDIRJFPB-FSGOGVSDSA-N (2z)-2-benzylidene-4-[(4-fluorophenyl)methyl]-n-[3-(3-methylpiperidin-1-yl)propyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1C(C)CCCN1CCCNC(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2CC=3C=CC(F)=CC=3)C2=C1 CKDUDHCDIRJFPB-FSGOGVSDSA-N 0.000 claims 1
- UPPDGSAXSCZMIE-ULJHMMPZSA-N (2z)-2-benzylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-3-oxo-4h-1,4-benzoxazine-6-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CC=C(O\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 UPPDGSAXSCZMIE-ULJHMMPZSA-N 0.000 claims 1
- ZPTWWFUWWUIMJG-YQYKVWLJSA-N (2z)-2-benzylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2CC=3C=CC(F)=CC=3)C2=C1 ZPTWWFUWWUIMJG-YQYKVWLJSA-N 0.000 claims 1
- MCOFBGSQGCDHEZ-VQNDASPWSA-N (2z)-2-benzylidene-n-[3-(3,4-dihydro-1h-isoquinolin-2-yl)propyl]-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CC1=CC=CC(CN2C3=CC(=CC=C3SC(/C2=O)=C\C=2C=CC=CC=2)C(=O)NCCCN2CC3=CC=CC=C3CC2)=C1 MCOFBGSQGCDHEZ-VQNDASPWSA-N 0.000 claims 1
- ABKKAJMGWBGMKT-MZFJOGFUSA-N (2z)-2-benzylidene-n-[3-(3,5-dimethylpiperidin-1-yl)propyl]-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1C(C)CC(C)CN1CCCNC(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2CC=3C=C(C)C=CC=3)C2=C1 ABKKAJMGWBGMKT-MZFJOGFUSA-N 0.000 claims 1
- URFNQMGOQKRVMA-MNBJERMJSA-N (2z)-2-benzylidene-n-[3-(3,5-dimethylpiperidin-1-yl)propyl]-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1C(C)CC(C)CN1CCCNC(=O)C1=CC=C(S\C(=C/C=2C=CC=CC=2)C(=O)N2CC=3C=CC(F)=CC=3)C2=C1 URFNQMGOQKRVMA-MNBJERMJSA-N 0.000 claims 1
- WVSOIRKWHGSDBF-UOZKZNBHSA-N (2z)-2-benzylidene-n-[3-(4-benzylpiperidin-1-yl)propyl]-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CC1=CC=CC(CN2C3=CC(=CC=C3SC(/C2=O)=C\C=2C=CC=CC=2)C(=O)NCCCN2CCC(CC=3C=CC=CC=3)CC2)=C1 WVSOIRKWHGSDBF-UOZKZNBHSA-N 0.000 claims 1
- KRIXOKLRGDHBEF-LAKKEJQSSA-N (2z)-2-benzylidene-n-[3-(4-benzylpiperidin-1-yl)propyl]-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=CC(F)=CC=C1CN(C\1=O)C2=CC(C(=O)NCCCN3CCC(CC=4C=CC=CC=4)CC3)=CC=C2SC/1=C\C1=CC=CC=C1 KRIXOKLRGDHBEF-LAKKEJQSSA-N 0.000 claims 1
- QLUVLAVLWYGIDK-QEOQBAOWSA-N (2z)-2-benzylidene-n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CC1=CC=CC(CN2C3=CC(=CC=C3SC(/C2=O)=C\C=2C=CC=CC=2)C(=O)NCCCN2CCN(CC2)C=2C(=CC=C(C)C=2)C)=C1 QLUVLAVLWYGIDK-QEOQBAOWSA-N 0.000 claims 1
- OZNJSWHDZNJELJ-LAKKEJQSSA-N (2z)-2-benzylidene-n-[3-[4-(4-methoxyphenyl)piperazin-1-yl]propyl]-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCNC(=O)C=2C=C3N(CC=4C=C(C)C=CC=4)C(=O)C(=C/C=4C=CC=CC=4)/SC3=CC=2)CC1 OZNJSWHDZNJELJ-LAKKEJQSSA-N 0.000 claims 1
- AFKBYNLPCUGDNZ-JDCMOKTRSA-N (2z)-2-benzylidene-n-[3-[cyclohexyl(methyl)amino]propyl]-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1CCCCC1N(C)CCCNC(=O)C(C=C1N(CC=2C=C(C)C=CC=2)C2=O)=CC=C1S\C2=C/C1=CC=CC=C1 AFKBYNLPCUGDNZ-JDCMOKTRSA-N 0.000 claims 1
- LJWIEDMDKQYRFI-YQYKVWLJSA-N (2z)-2-benzylidene-n-[3-[cyclohexyl(methyl)amino]propyl]-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1CCCCC1N(C)CCCNC(=O)C(C=C1N(CC=2C=CC(F)=CC=2)C2=O)=CC=C1S\C2=C/C1=CC=CC=C1 LJWIEDMDKQYRFI-YQYKVWLJSA-N 0.000 claims 1
- JGTGDLPPNWPTOU-JNPMABBASA-N (2z)-4-(cyclohexylmethyl)-2-ethylidene-3-imino-n-(3-piperidin-1-ylpropyl)-1,4-benzothiazine-6-carboxamide Chemical compound N=C1C(=C/C)/SC2=CC=C(C(=O)NCCCN3CCCCC3)C=C2N1CC1CCCCC1 JGTGDLPPNWPTOU-JNPMABBASA-N 0.000 claims 1
- YKGKLDCCJVPCMH-JNPMABBASA-N (2z)-4-benzyl-2-ethylidene-3-imino-n-(3-piperidin-1-ylpropyl)-1,4-benzothiazine-6-carboxamide Chemical compound N=C1C(=C/C)/SC2=CC=C(C(=O)NCCCN3CCCCC3)C=C2N1CC1=CC=CC=C1 YKGKLDCCJVPCMH-JNPMABBASA-N 0.000 claims 1
- KMXBZHVWLSKBEV-UJOWUYHQSA-N (2z)-4-benzyl-2-ethylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CC=C(S\C(=C/C)C(=O)N2CC=3C=CC=CC=3)C2=C1 KMXBZHVWLSKBEV-UJOWUYHQSA-N 0.000 claims 1
- FCSGHIXIKQWVJQ-OFWBYEQRSA-N (2z)-n-[2-(azepan-1-yl)ethyl]-2-benzylidene-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CC1=CC=CC(CN2C3=CC(=CC=C3SC(/C2=O)=C\C=2C=CC=CC=2)C(=O)NCCN2CCCCCC2)=C1 FCSGHIXIKQWVJQ-OFWBYEQRSA-N 0.000 claims 1
- SEDBWQZCSWCKCN-BRPDVVIDSA-N (2z)-n-[2-(azepan-1-yl)ethyl]-2-benzylidene-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=CC(F)=CC=C1CN(C\1=O)C2=CC(C(=O)NCCN3CCCCCC3)=CC=C2SC/1=C\C1=CC=CC=C1 SEDBWQZCSWCKCN-BRPDVVIDSA-N 0.000 claims 1
- PKZGRULQWBETTD-XHPQRKPJSA-N (2z)-n-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]-2-[2-(4-methoxyphenyl)-2-oxoethylidene]-3-oxo-1,4-dihydroquinoxaline-6-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C/1C(=O)NC2=CC(C(=O)NCCN3CCN(CC3)C=3C(=CC=CC=3)F)=CC=C2N\1 PKZGRULQWBETTD-XHPQRKPJSA-N 0.000 claims 1
- PRHVFPJWIANYKA-VAMRJTSQSA-N (2z)-n-[3-(azepan-1-yl)propyl]-2-benzylidene-4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CC1=CC=CC(CN2C3=CC(=CC=C3SC(/C2=O)=C\C=2C=CC=CC=2)C(=O)NCCCN2CCCCCC2)=C1 PRHVFPJWIANYKA-VAMRJTSQSA-N 0.000 claims 1
- MCXJXPMWORNTRY-OFWBYEQRSA-N (2z)-n-[3-(azepan-1-yl)propyl]-2-benzylidene-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=CC(F)=CC=C1CN(C\1=O)C2=CC(C(=O)NCCCN3CCCCCC3)=CC=C2SC/1=C\C1=CC=CC=C1 MCXJXPMWORNTRY-OFWBYEQRSA-N 0.000 claims 1
- CBEAGAZKXXEFFO-BRPDVVIDSA-N (2z)-n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-4-methyl-2-[(3-methylphenyl)methylidene]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=C2N(C)C(=O)\C(=C\C=3C=C(C)C=CC=3)SC2=CC=C1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1F CBEAGAZKXXEFFO-BRPDVVIDSA-N 0.000 claims 1
- REUPKBWPTUKOGH-ANYBSYGZSA-N (2z)-n-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]-4-methyl-2-[(2-methylphenyl)methylidene]-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound C1=C2N(C)C(=O)\C(=C\C=3C(=CC=CC=3)C)SC2=CC=C1C(=O)NCCCN(CC1)CCN1C1=CC=C(F)C=C1 REUPKBWPTUKOGH-ANYBSYGZSA-N 0.000 claims 1
- MLANGIZDTNVKMF-KJDXXRKVSA-N (3z)-1-(cyclohexylmethyl)-3-ethylidene-n-(3-piperidin-1-ylpropyl)-2-sulfanylidenepyrido[2,3-b][1,4]oxazine-7-carboxamide Chemical compound S=C1C(=C/C)/OC2=NC=C(C(=O)NCCCN3CCCCC3)C=C2N1CC1CCCCC1 MLANGIZDTNVKMF-KJDXXRKVSA-N 0.000 claims 1
- SZZRKSZNXOMBEA-QDPJQKAKSA-N (3z)-1-(cyclohexylmethyl)-3-ethylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-oxopyrido[2,3-b][1,4]oxazine-7-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CN=C(O\C(=C/C)C(=O)N2CC3CCCCC3)C2=C1 SZZRKSZNXOMBEA-QDPJQKAKSA-N 0.000 claims 1
- RLWIGFXZNKSWNQ-QDPJQKAKSA-N (3z)-1-benzyl-3-ethylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-oxopyrido[2,3-b][1,4]oxazine-7-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CN=C(O\C(=C/C)C(=O)N2CC=3C=CC=CC=3)C2=C1 RLWIGFXZNKSWNQ-QDPJQKAKSA-N 0.000 claims 1
- UQPTYUAABLSMQJ-JCMHNJIXSA-N (3z)-3-benzylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-oxo-1h-pyrido[2,3-b][1,4]oxazine-7-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CN=C(O\C(=C/C=2C=CC=CC=2)C(=O)N2)C2=C1 UQPTYUAABLSMQJ-JCMHNJIXSA-N 0.000 claims 1
- LVZGCMDULWACTD-JCMHNJIXSA-N (3z)-3-benzylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-oxo-1h-pyrido[3,4-b][1,4]oxazine-7-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C(N=C1)=CC(NC\2=O)=C1OC/2=C\C1=CC=CC=C1 LVZGCMDULWACTD-JCMHNJIXSA-N 0.000 claims 1
- ASNAMFOQBWJDJF-JCMHNJIXSA-N (3z)-3-benzylidene-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-oxo-1h-pyrido[3,4-b][1,4]thiazine-7-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C(N=C1)=CC(NC\2=O)=C1SC/2=C\C1=CC=CC=C1 ASNAMFOQBWJDJF-JCMHNJIXSA-N 0.000 claims 1
- RYLWZVQMOLCDHR-KJDXXRKVSA-N (3z)-3-ethylidene-4-[(4-fluorophenyl)methyl]-2-oxo-n-(3-piperidin-1-ylpropyl)-1,4-benzothiazine-7-carboxamide Chemical compound C12=CC=C(C(=O)NCCCN3CCCCC3)C=C2SC(=O)C(=C/C)/N1CC1=CC=C(F)C=C1 RYLWZVQMOLCDHR-KJDXXRKVSA-N 0.000 claims 1
- FDPCLZWXBWEYTK-KJDXXRKVSA-N (3z)-3-ethylidene-4-[(4-fluorophenyl)methyl]-n-(3-piperidin-1-ylpropyl)-2-sulfanylidene-1,4-benzoxazine-7-carboxamide Chemical compound C12=CC=C(C(=O)NCCCN3CCCCC3)C=C2OC(=S)C(=C/C)/N1CC1=CC=C(F)C=C1 FDPCLZWXBWEYTK-KJDXXRKVSA-N 0.000 claims 1
- UBVBYNGWDZNKKE-MHZLTWQESA-N (4ar)-n-[2-(4-benzylpiperidin-1-yl)ethyl]-7-[(2-chlorophenyl)methyl]-6-oxo-3,4,4a,5-tetrahydrothiopyrano[4,3-d][1]benzazepine-9-carboxamide Chemical compound ClC1=CC=CC=C1CN1C(=O)C[C@@H]2CCSC=C2C2=CC=C(C(=O)NCCN3CCC(CC=4C=CC=CC=4)CC3)C=C21 UBVBYNGWDZNKKE-MHZLTWQESA-N 0.000 claims 1
- SAQPYRVXAHTKJL-RUZDIDTESA-N (7ar)-n-[2-(4-benzylpiperidin-1-yl)ethyl]-5-methyl-6-oxo-7,7a,8,9,10,11-hexahydropyrido[1,2-a][1,5]benzodiazepine-3-carboxamide Chemical compound C([C@H]1CCCCN1C1=CC=2)C(=O)N(C)C1=CC=2C(=O)NCCN(CC1)CCC1CC1=CC=CC=C1 SAQPYRVXAHTKJL-RUZDIDTESA-N 0.000 claims 1
- GPNKGXCKRXUKDC-DHIFEGFHSA-N (7as,11as)-n-[2-(4-benzylpiperidin-1-yl)ethyl]-5-[(2-chloro-5-fluorophenyl)methyl]-6-oxo-7a,8,9,10,11,11a-hexahydro-7h-benzo[d][1]benzazepine-3-carboxamide Chemical compound FC1=CC=C(Cl)C(CN2C(C[C@@H]3CCCC[C@@H]3C3=CC=C(C=C32)C(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=O)=C1 GPNKGXCKRXUKDC-DHIFEGFHSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- XCQNYGODYITLNC-UHFFFAOYSA-N 10-(1,4-dioxan-2-ylmethylamino)-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCC3OCCOC3)=C3C1=C2C1=CC=CC=C1C3=O XCQNYGODYITLNC-UHFFFAOYSA-N 0.000 claims 1
- NJMQVXQJGLMIPF-UHFFFAOYSA-N 10-(3-ethoxypropylamino)-14-[[4-(furan-2-carbonyl)piperazin-1-yl]methyl]-15-oxatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound O1C(=C23)C4=CC=CC=C4C(=O)C3=C(NCCCOCC)C=CC2=C1CN(CC1)CCN1C(=O)C1=CC=CO1 NJMQVXQJGLMIPF-UHFFFAOYSA-N 0.000 claims 1
- IXVGQXLEJNSZAI-UHFFFAOYSA-N 10-(benzylamino)-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCC=3C=CC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O IXVGQXLEJNSZAI-UHFFFAOYSA-N 0.000 claims 1
- OJXNTLCYXFEZMJ-UHFFFAOYSA-N 10-(cyclopenta-1,3-dien-1-ylmethylamino)-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCC=3CC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O OJXNTLCYXFEZMJ-UHFFFAOYSA-N 0.000 claims 1
- RRLMEVXFNDWYLG-UHFFFAOYSA-N 10-(hydroxymethylamino)-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCO)=C3C1=C2C1=CC=CC=C1C3=O RRLMEVXFNDWYLG-UHFFFAOYSA-N 0.000 claims 1
- MILKDKBUJOBVHR-UHFFFAOYSA-N 10-[2-(1,4-dioxan-2-yl)ethyl]-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(CCC3OCCOC3)=C3C1=C2C1=CC=CC=C1C3=O MILKDKBUJOBVHR-UHFFFAOYSA-N 0.000 claims 1
- LQWGKRJUVRUIGH-UHFFFAOYSA-N 10-[2-(1,4-dioxin-2-yl)ethyl]-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(CCC=3OC=COC=3)=C3C1=C2C1=CC=CC=C1C3=O LQWGKRJUVRUIGH-UHFFFAOYSA-N 0.000 claims 1
- JAXYGKVTQLLZKN-UHFFFAOYSA-N 10-[2-(furan-2-yl)ethyl]-12-(4-methylpiperazin-1-yl)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(CCC=3OC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O JAXYGKVTQLLZKN-UHFFFAOYSA-N 0.000 claims 1
- JXBZSZXDUTULRY-UHFFFAOYSA-N 12-(4-cyclohexylpiperazin-1-yl)-10-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)anilino]-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1=CC(C(O)(C(F)(F)F)C(F)(F)F)=CC=C1NC(C=C1N2CCN(CC2)C2CCCCC2)=C2C(=O)C3=CC=CC=C3C3=C2C1=NO3 JXBZSZXDUTULRY-UHFFFAOYSA-N 0.000 claims 1
- TYNWIEWAXMRPJH-UHFFFAOYSA-N 12-(4-cyclohexylpiperazin-1-yl)-10-[4-(2H-tetrazol-5-yl)anilino]-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1=2C=3C(=O)C4=CC=CC=C4C=2ON=C1C(N1CCN(CC1)C1CCCCC1)=CC=3NC(C=C1)=CC=C1C1=NN=NN1 TYNWIEWAXMRPJH-UHFFFAOYSA-N 0.000 claims 1
- OOPSWBHGUWRBOP-UHFFFAOYSA-N 12-(4-methylpiperazin-1-yl)-10-(pyrazin-2-ylmethylamino)-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCC=3N=CC=NC=3)=C3C1=C2C1=CC=CC=C1C3=O OOPSWBHGUWRBOP-UHFFFAOYSA-N 0.000 claims 1
- ZTPZBVPYPAUQCU-UHFFFAOYSA-N 13-(furan-2-ylmethylamino)-15-(4-propylpiperazin-1-yl)-5,7,18-trioxapentacyclo[10.6.1.02,10.04,8.016,19]nonadeca-1(19),2,4(8),9,12,14,16-heptaen-11-one Chemical compound C1CN(CCC)CCN1C(C1=CO2)=CC(NCC=3OC=CC=3)=C3C1=C2C1=CC(OCO2)=C2C=C1C3=O ZTPZBVPYPAUQCU-UHFFFAOYSA-N 0.000 claims 1
- NQWJFRVQYWIXEK-UHFFFAOYSA-N 14-[(4-cyclohexylpiperazin-1-yl)methyl]-10-(furan-2-ylmethylamino)-15-oxatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-8-one Chemical compound C1=2C=3C=CC(NCC=4OC=CC=4)=C1C(=O)C1=CC=CC=C1C=2OC=3CN(CC1)CCN1C1CCCCC1 NQWJFRVQYWIXEK-UHFFFAOYSA-N 0.000 claims 1
- SKEPGOHGQVXXOH-VFCFBJKWSA-N 2-[(2e)-2-[(2-chlorophenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]acetamide Chemical compound C1=CC(F)=CC=C1N1CCN(CCCNC(=O)CN2C3=CC=CC=C3SC(/C2=O)=C/C=2C(=CC=CC=2)Cl)CC1 SKEPGOHGQVXXOH-VFCFBJKWSA-N 0.000 claims 1
- HWTJIZBHSANFNM-ZTKZIYFRSA-N 2-[(2e)-2-[(3-bromo-4-methoxyphenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]acetamide Chemical compound C1=C(Br)C(OC)=CC=C1\C=C\1C(=O)N(CC(=O)NCCCN2CCN(CC2)C=2C(=CC=CC=2)F)C2=CC=CC=C2S/1 HWTJIZBHSANFNM-ZTKZIYFRSA-N 0.000 claims 1
- SURXACJKVOHVQF-ZTKZIYFRSA-N 2-[(2e)-2-[(3-bromo-4-methoxyphenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]acetamide Chemical compound C1=C(Br)C(OC)=CC=C1\C=C\1C(=O)N(CC(=O)NCCCN2CCN(CC2)C=2C=CC(F)=CC=2)C2=CC=CC=C2S/1 SURXACJKVOHVQF-ZTKZIYFRSA-N 0.000 claims 1
- OVABVIKSAZHEDX-LGUFXXKBSA-N 2-[(2e)-2-[(3-bromophenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[2-[methyl(2-phenylethyl)amino]ethyl]acetamide Chemical compound C=1C=CC=CC=1CCN(C)CCNC(=O)CN(C1=CC=CC=C1S1)C(=O)\C1=C/C1=CC=CC(Br)=C1 OVABVIKSAZHEDX-LGUFXXKBSA-N 0.000 claims 1
- SYOPKFUDLHSWBX-RRAHZORUSA-N 2-[(2z)-2-[(3-chlorophenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]acetamide Chemical compound FC1=CC=CC=C1N1CCN(CCCNC(=O)CN2C3=CC=CC=C3SC(/C2=O)=C\C=2C=C(Cl)C=CC=2)CC1 SYOPKFUDLHSWBX-RRAHZORUSA-N 0.000 claims 1
- LGRJBEIFRHQNTE-USHMODERSA-N 2-[(2z)-2-[(3-chlorophenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]acetamide Chemical compound ClC1=CC=CC(\C=C/2C(N(CC(=O)NCCCN3CCN(CC3)C=3C=C(Cl)C=CC=3)C3=CC=CC=C3S\2)=O)=C1 LGRJBEIFRHQNTE-USHMODERSA-N 0.000 claims 1
- SYKYJEKWXUYITN-RRAHZORUSA-N 2-[(2z)-2-[(3-chlorophenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]acetamide Chemical compound C1=CC(F)=CC=C1N1CCN(CCCNC(=O)CN2C3=CC=CC=C3SC(/C2=O)=C\C=2C=C(Cl)C=CC=2)CC1 SYKYJEKWXUYITN-RRAHZORUSA-N 0.000 claims 1
- GQWYTYKEEPEOOX-ANYBSYGZSA-N 2-[(2z)-2-[(3-chlorophenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]-n-[3-[4-(4-methoxyphenyl)piperazin-1-yl]propyl]acetamide Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCNC(=O)CN2C3=CC=CC=C3SC(/C2=O)=C\C=2C=C(Cl)C=CC=2)CC1 GQWYTYKEEPEOOX-ANYBSYGZSA-N 0.000 claims 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 claims 1
- MKXPSKGYFCRKOZ-HYARGMPZSA-N 4-[(e)-[4-[(2-fluorophenyl)methyl]-3-oxo-1,4-benzoxazin-2-ylidene]methyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1\C=C\1C(=O)N(CC=2C(=CC=CC=2)F)C2=CC=CC=C2O/1 MKXPSKGYFCRKOZ-HYARGMPZSA-N 0.000 claims 1
- CLLZPIUZJCWBOZ-MTDXEUNCSA-N 4-[(e)-[4-[(3-chlorophenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]-n-[(1-ethylpyrrolidin-2-yl)methyl]benzamide Chemical compound CCN1CCCC1CNC(=O)C(C=C1)=CC=C1\C=C\1C(=O)N(CC=2C=C(Cl)C=CC=2)C2=CC=CC=C2S/1 CLLZPIUZJCWBOZ-MTDXEUNCSA-N 0.000 claims 1
- LMCYHBAQCSMHHI-UQRQXUALSA-N 4-[(e)-[4-[(3-chlorophenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]-n-[2-(dibutylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)NCCN(CCCC)CCCC)=CC=C1\C=C\1C(=O)N(CC=2C=C(Cl)C=CC=2)C2=CC=CC=C2S/1 LMCYHBAQCSMHHI-UQRQXUALSA-N 0.000 claims 1
- HGUSGQYXLIOROY-JGRMKTMXSA-N 4-[(e)-[4-[(3-chlorophenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]-n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]benzamide Chemical compound FC1=CC=CC=C1N1CCN(CCCNC(=O)C=2C=CC(\C=C\3C(N(CC=4C=C(Cl)C=CC=4)C4=CC=CC=C4S/3)=O)=CC=2)CC1 HGUSGQYXLIOROY-JGRMKTMXSA-N 0.000 claims 1
- XNRQJTFHMVNFKH-DFKUXCBWSA-N 4-[(e)-[4-[(3-chlorophenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]-n-[3-[cyclohexyl(methyl)amino]propyl]benzamide Chemical compound C1CCCCC1N(C)CCCNC(=O)C(C=C1)=CC=C1\C=C(C1=O)\SC2=CC=CC=C2N1CC1=CC=CC(Cl)=C1 XNRQJTFHMVNFKH-DFKUXCBWSA-N 0.000 claims 1
- MKXPSKGYFCRKOZ-HMAPJEAMSA-N 4-[(z)-[4-[(2-fluorophenyl)methyl]-3-oxo-1,4-benzoxazin-2-ylidene]methyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1\C=C/1C(=O)N(CC=2C(=CC=CC=2)F)C2=CC=CC=C2O\1 MKXPSKGYFCRKOZ-HMAPJEAMSA-N 0.000 claims 1
- REZNUNMESSPGNR-HMAPJEAMSA-N 4-[(z)-[4-[(4-chlorophenyl)methyl]-3-oxo-1,4-benzoxazin-2-ylidene]methyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1\C=C/1C(=O)N(CC=2C=CC(Cl)=CC=2)C2=CC=CC=C2O\1 REZNUNMESSPGNR-HMAPJEAMSA-N 0.000 claims 1
- JSTINVLFYWCNRF-UHFFFAOYSA-N 4-[[12-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-8-oxo-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-10-yl]amino]benzoic acid Chemical compound C1CN(C)CCC1N1CCN(C=2C3=NOC=4C5=CC=CC=C5C(=O)C(C3=4)=C(NC=3C=CC(=CC=3)C(O)=O)C=2)CC1 JSTINVLFYWCNRF-UHFFFAOYSA-N 0.000 claims 1
- CPMQVKHRKXYPMD-UHFFFAOYSA-N 4-benzyl-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-imino-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CC=C(SC(=N)C(=O)N2CC=3C=CC=CC=3)C2=C1 CPMQVKHRKXYPMD-UHFFFAOYSA-N 0.000 claims 1
- QCMOMBAWUUBHRT-UHFFFAOYSA-N 4-benzyl-n-[3-(2-ethylpiperidin-1-yl)propyl]-2-imino-3-oxo-1,4-benzoxazine-6-carboxamide Chemical compound CCC1CCCCN1CCCNC(=O)C1=CC=C(OC(=N)C(=O)N2CC=3C=CC=CC=3)C2=C1 QCMOMBAWUUBHRT-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- HBPMDANOKYGWBO-UHFFFAOYSA-N 5-[(2-chloro-5-fluorophenyl)methyl]-6-oxo-n-[2-(4-phenylpiperazin-1-yl)ethyl]benzo[b][1,4]benzothiazepine-3-carboxamide Chemical compound FC1=CC=C(Cl)C(CN2C(C3=CC=CC=C3SC3=CC=C(C=C32)C(=O)NCCN2CCN(CC2)C=2C=CC=CC=2)=O)=C1 HBPMDANOKYGWBO-UHFFFAOYSA-N 0.000 claims 1
- OPXOXXIZLWDDBG-UHFFFAOYSA-N 5-[(2-fluorophenyl)methyl]-n-[3-(4-phenylpiperazin-1-yl)propyl]-6-sulfanylidene-8h-pyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound FC1=CC=CC=C1CN1C2=CC(C(=O)NCCCN3CCN(CC3)C=3C=CC=CC=3)=CC=C2N2C=CCC=C2C1=S OPXOXXIZLWDDBG-UHFFFAOYSA-N 0.000 claims 1
- YXQWXFDZTHGLIT-UHFFFAOYSA-N 5-[(2-fluorophenyl)methyl]-n-[3-(4-phenylpiperazin-1-yl)propyl]-6-sulfanylidenephenanthridine-3-carboxamide Chemical compound FC1=CC=CC=C1CN1C(=S)C2=CC=CC=C2C2=CC=C(C(=O)NCCCN3CCN(CC3)C=3C=CC=CC=3)C=C21 YXQWXFDZTHGLIT-UHFFFAOYSA-N 0.000 claims 1
- NFDFQDUWKQCAJP-UHFFFAOYSA-N 5-[(3-chlorophenyl)methyl]-6-oxo-n-[3-(4-phenylpiperazin-1-yl)propyl]benzo[b][1,4]benzothiazepine-3-carboxamide Chemical compound ClC1=CC=CC(CN2C(C3=CC=CC=C3SC3=CC=C(C=C32)C(=O)NCCCN2CCN(CC2)C=2C=CC=CC=2)=O)=C1 NFDFQDUWKQCAJP-UHFFFAOYSA-N 0.000 claims 1
- IVANAUWYAWTXJH-UHFFFAOYSA-N 5-benzyl-6-oxo-n-[3-(4-phenylpiperazin-1-yl)propyl]-7,8,9,10-tetrahydrophenanthridine-3-carboxamide Chemical compound C=1C=C2C=3CCCCC=3C(=O)N(CC=3C=CC=CC=3)C2=CC=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1 IVANAUWYAWTXJH-UHFFFAOYSA-N 0.000 claims 1
- DNTSZCVGTLORNV-UHFFFAOYSA-N 5-benzyl-n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-6-oxo-7,8,9,10-tetrahydro-6ah-pyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C=C3N(CC=4C=CC=CC=4)C(=O)C4CCCCN4C3=CC=2)CC1 DNTSZCVGTLORNV-UHFFFAOYSA-N 0.000 claims 1
- BAMYHSSMKDHRDA-UHFFFAOYSA-N 5-benzyl-n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-6-oxophenanthridine-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C=C3C(C4=CC=CC=C4C(=O)N3CC=3C=CC=CC=3)=CC=2)CC1 BAMYHSSMKDHRDA-UHFFFAOYSA-N 0.000 claims 1
- OWQKCSRDBBHFAT-UHFFFAOYSA-N 6-benzyl-5-oxo-n-[3-(4-phenylpiperazin-1-yl)propyl]benzo[c][2,6]naphthyridine-8-carboxamide Chemical compound C=1C=C(C2=CN=CC=C2C(=O)N2CC=3C=CC=CC=3)C2=CC=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1 OWQKCSRDBBHFAT-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- NTNTUDCQKJLBLM-ROMGYVFFSA-N C1=CC(C(=O)NC)=CC=C1\N=C/1C(=O)N(CC=2C(=CC=CC=2)F)C(C=CC=C2)=C2O\1 Chemical compound C1=CC(C(=O)NC)=CC=C1\N=C/1C(=O)N(CC=2C(=CC=CC=2)F)C(C=CC=C2)=C2O\1 NTNTUDCQKJLBLM-ROMGYVFFSA-N 0.000 claims 1
- NTNTUDCQKJLBLM-XTCLZLMSSA-N C1=CC(C(=O)NC)=CC=C1\N=C\1C(=O)N(CC=2C(=CC=CC=2)F)C(C=CC=C2)=C2O/1 Chemical compound C1=CC(C(=O)NC)=CC=C1\N=C\1C(=O)N(CC=2C(=CC=CC=2)F)C(C=CC=C2)=C2O/1 NTNTUDCQKJLBLM-XTCLZLMSSA-N 0.000 claims 1
- DXYDBSRMZAADMW-UHFFFAOYSA-N C1CN(C)CCN1C(C1=NO2)=CC(NCC=3NC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCC=3NC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O DXYDBSRMZAADMW-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 206010067601 Dysmyelination Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- GSPXULNZVLZLGU-UHFFFAOYSA-N N-[4-[[12-(4-cyclohexylpiperazin-1-yl)-8-oxo-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-10-yl]amino]phenyl]sulfonylacetamide Chemical compound C1=CC(S(=O)(=O)NC(=O)C)=CC=C1NC(C=C1N2CCN(CC2)C2CCCCC2)=C2C(=O)C3=CC=CC=C3C3=C2C1=NO3 GSPXULNZVLZLGU-UHFFFAOYSA-N 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000010261 Small Fiber Neuropathy Diseases 0.000 claims 1
- 206010073928 Small fibre neuropathy Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- MEHKXGDAMQKVMG-UHFFFAOYSA-N ac1mtixo Chemical compound C1=CC(C(=O)OC)=CC=C1NC(C=C1N2CCN(CC2)C2CCCCC2)=C2C(=O)C3=CC=CC=C3C3=C2C1=NO3 MEHKXGDAMQKVMG-UHFFFAOYSA-N 0.000 claims 1
- MMUWXZUTOXDAGI-UHFFFAOYSA-N ac1muhiz Chemical compound C1=CC(C(=O)O)=CC=C1NC(C=C1N2CCN(CC2)C2CCCCC2)=C2C(=O)C3=CC=CC=C3C3=C2C1=NO3 MMUWXZUTOXDAGI-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000011496 cAMP-mediated signaling Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000009390 immune abnormality Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000021646 inflammation of heart layer Diseases 0.000 claims 1
- 239000003983 inhalation anesthetic agent Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- CGPQLWHCJSKOEG-UHFFFAOYSA-N molport-007-586-222 Chemical compound C1CN(CCC)CCN1C(C1=NO2)=CC(NC=3C=CC(OCC)=CC=3)=C3C1=C2C1=CC=CC=C1C3=O CGPQLWHCJSKOEG-UHFFFAOYSA-N 0.000 claims 1
- SXZGFLAFVPWCHZ-UHFFFAOYSA-N molport-007-586-225 Chemical compound C1CN(CCC)CCN1C(C1=NO2)=CC(NC=3C=C4OCCOC4=CC=3)=C3C1=C2C1=CC=CC=C1C3=O SXZGFLAFVPWCHZ-UHFFFAOYSA-N 0.000 claims 1
- HJTDDTXPKNBMHT-UHFFFAOYSA-N molport-007-586-228 Chemical compound C1CN(CCC)CCN1C(C1=NO2)=CC(NC=3C=CC(=CC=3)C(=O)OC)=C3C1=C2C1=CC=CC=C1C3=O HJTDDTXPKNBMHT-UHFFFAOYSA-N 0.000 claims 1
- PSCOBZNLAHXYKZ-UHFFFAOYSA-N molport-007-586-462 Chemical compound COC1=CC=C(Cl)C=C1CN1CCN(C=2C3=NOC=4C5=CC=CC=C5C(=O)C(C3=4)=C(NC=3C=CC(=CC=3)C(O)=O)C=2)CC1 PSCOBZNLAHXYKZ-UHFFFAOYSA-N 0.000 claims 1
- IQRNRLGHLRNYJH-UHFFFAOYSA-N molport-007-586-475 Chemical compound C1=2C3=NOC=2C2=CC=CC=C2C(=O)C1=C(NCCCC(=O)O)C=C3N(CC1)CCN1C1CCCCC1 IQRNRLGHLRNYJH-UHFFFAOYSA-N 0.000 claims 1
- MWFXQMSQSAVQEQ-UHFFFAOYSA-N molport-007-651-346 Chemical compound C1=2C3=NOC=2C2=CC=CC=C2C(=O)C1=C(NCCCC)C=C3N(CC1)CCN1C1CCCCC1 MWFXQMSQSAVQEQ-UHFFFAOYSA-N 0.000 claims 1
- QZYHYLJCOJLHDP-UHFFFAOYSA-N molport-007-651-380 Chemical compound C1=2C=3C(=O)C4=CC=CC=C4C=2ON=C1C(N1CCN(CC1)C1CCCCC1)=CC=3NC1CCCCC1 QZYHYLJCOJLHDP-UHFFFAOYSA-N 0.000 claims 1
- OBAPRJSKURHXID-UHFFFAOYSA-N molport-007-651-527 Chemical compound C1CN(C)CCN1C(C1=NO2)=CC(NCC=3OC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O OBAPRJSKURHXID-UHFFFAOYSA-N 0.000 claims 1
- AQWASLBEMRXALT-UHFFFAOYSA-N molport-007-651-529 Chemical compound C1=2C=3C(=O)C4=CC=CC=C4C=2ON=C1C(N1CCN(CC1)C1CCCCC1)=CC=3NCC1=CC=CO1 AQWASLBEMRXALT-UHFFFAOYSA-N 0.000 claims 1
- CWMDFOOJJLAJES-UHFFFAOYSA-N molport-007-651-536 Chemical compound C1CN(CCC)CCN1C(C1=NO2)=CC(NCC=3OC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O CWMDFOOJJLAJES-UHFFFAOYSA-N 0.000 claims 1
- UTQKRBMLMVUGOE-UHFFFAOYSA-N molport-007-651-542 Chemical compound C1CN(CCO)CCN1C(C1=NO2)=CC(NCC=3OC=CC=3)=C3C1=C2C1=CC=CC=C1C3=O UTQKRBMLMVUGOE-UHFFFAOYSA-N 0.000 claims 1
- LRFNWTDTJZCQPI-UHFFFAOYSA-N molport-007-651-609 Chemical compound C1CN(C2=C3C(=O)C4=CC=CC=C4C=4ON=C(C3=4)C(N3CCN(CC=4C=C5OCOC5=CC=4)CC3)=C2)CCN1C(=O)C1=CC=CO1 LRFNWTDTJZCQPI-UHFFFAOYSA-N 0.000 claims 1
- BMDAQLFMMMEVLR-UHFFFAOYSA-N molport-007-651-713 Chemical compound C1=2C3=NOC=2C2=CC=CC=C2C(=O)C1=C(NCCCOCC)C=C3N(CC1)CCN1C1CCCCC1 BMDAQLFMMMEVLR-UHFFFAOYSA-N 0.000 claims 1
- KIKRPEVNWZHOBB-AVLPFNLUSA-N n-[2-(4-benzylpiperidin-1-yl)ethyl]-4-[(e)-[4-[(2,5-dimethylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide Chemical compound CC1=CC=C(C)C(CN2C3=CC=CC=C3SC(/C2=O)=C/C=2C=CC(=CC=2)C(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=C1 KIKRPEVNWZHOBB-AVLPFNLUSA-N 0.000 claims 1
- SJBLVWNEJMJSRI-UHFFFAOYSA-N n-[2-(4-benzylpiperidin-1-yl)ethyl]-5-[(2-chloro-5-fluorophenyl)methyl]-6-oxobenzo[b][1,4]benzothiazepine-3-carboxamide Chemical compound FC1=CC=C(Cl)C(CN2C(C3=CC=CC=C3SC3=CC=C(C=C32)C(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=O)=C1 SJBLVWNEJMJSRI-UHFFFAOYSA-N 0.000 claims 1
- ZLIPQXLYDGRRIZ-UHFFFAOYSA-N n-[2-(4-benzylpiperidin-1-yl)ethyl]-6-[(3-fluorophenyl)methyl]-5-oxopyrido[2,3-b][1,5]benzoxazepine-8-carboxamide Chemical compound FC1=CC=CC(CN2C(C3=CC=CN=C3OC3=CC=C(C=C32)C(=O)NCCN2CCC(CC=3C=CC=CC=3)CC2)=O)=C1 ZLIPQXLYDGRRIZ-UHFFFAOYSA-N 0.000 claims 1
- HOECYHHQTPIPHJ-UHFFFAOYSA-N n-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-6-methyl-5,11-dioxopyrido[4,3-c][1]benzazepine-8-carboxamide Chemical compound C=1C=C2C(=O)C3=CN=CC=C3C(=O)N(C)C2=CC=1C(=O)NCCN(CC1)CCN1C1CCCCC1 HOECYHHQTPIPHJ-UHFFFAOYSA-N 0.000 claims 1
- IZLMCFZJNLUALV-UHFFFAOYSA-N n-[2-(4-cyclopenta-1,3-dien-1-ylpiperazin-1-yl)ethyl]-5-[(5-fluoro-2-methylphenyl)methyl]-6-oxo-11h-dipyrido[3,2-a:3',2'-e][1,4]diazepine-3-carboxamide Chemical compound CC1=CC=C(F)C=C1CN1C(=O)C2=CC=CN=C2NC2=NC=C(C(=O)NCCN3CCN(CC3)C=3CC=CC=3)C=C21 IZLMCFZJNLUALV-UHFFFAOYSA-N 0.000 claims 1
- DAIZMNHPGARFCZ-JBASAIQMSA-N n-[2-(dipropylamino)ethyl]-4-[(e)-[4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide Chemical compound C1=CC(C(=O)NCCN(CCC)CCC)=CC=C1\C=C\1C(=O)N(CC=2C=C(C)C=CC=2)C2=CC=CC=C2S/1 DAIZMNHPGARFCZ-JBASAIQMSA-N 0.000 claims 1
- JOEJJNBGNINENO-DFKUXCBWSA-N n-[3-(4-benzylpiperidin-1-yl)propyl]-2-[(2e)-2-[(3-bromo-4-methoxyphenyl)methylidene]-3-oxo-1,4-benzothiazin-4-yl]acetamide Chemical compound C1=C(Br)C(OC)=CC=C1\C=C\1C(=O)N(CC(=O)NCCCN2CCC(CC=3C=CC=CC=3)CC2)C2=CC=CC=C2S/1 JOEJJNBGNINENO-DFKUXCBWSA-N 0.000 claims 1
- COILEDMLNFDNSA-UHFFFAOYSA-N n-[3-[4-(1,3-benzodioxol-5-yl)piperazin-1-yl]propyl]-6-oxo-5,6a,7,8,9,10-hexahydropyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound C1CCCC2C(=O)NC3=CC(C(NCCCN4CCN(CC4)C=4C=C5OCOC5=CC=4)=O)=CC=C3N21 COILEDMLNFDNSA-UHFFFAOYSA-N 0.000 claims 1
- RTUKCVKFLZIPMO-KVQDIILNSA-N n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-4-[(e)-[4-[(2-methylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide Chemical compound CC1=CC=CC=C1CN(C\1=O)C2=CC=CC=C2SC/1=C/C1=CC=C(C(=O)NCCCN2CCN(CC2)C=2C(=CC=CC=2)F)C=C1 RTUKCVKFLZIPMO-KVQDIILNSA-N 0.000 claims 1
- GTJFLBZANNACIW-KVQDIILNSA-N n-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-4-[(e)-[4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide Chemical compound CC1=CC=CC(CN2C3=CC=CC=C3SC(/C2=O)=C/C=2C=CC(=CC=2)C(=O)NCCCN2CCN(CC2)C=2C(=CC=CC=2)F)=C1 GTJFLBZANNACIW-KVQDIILNSA-N 0.000 claims 1
- LYCFOZYXVTVABL-UHFFFAOYSA-N n-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-6-oxo-5,6a,7,8,9,10-hexahydropyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound ClC1=CC=CC(N2CCN(CCCNC(=O)C=3C=C4NC(=O)C5CCCCN5C4=CC=3)CC2)=C1 LYCFOZYXVTVABL-UHFFFAOYSA-N 0.000 claims 1
- ZJMDEXSCFWRKIZ-UHFFFAOYSA-N n-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-6-oxo-5,8,9,10-tetrahydropyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound ClC1=CC=CC(N2CCN(CCCNC(=O)C=3C=C4NC(=O)C5=CCCCN5C4=CC=3)CC2)=C1 ZJMDEXSCFWRKIZ-UHFFFAOYSA-N 0.000 claims 1
- VLJWMOHTHSOGFV-LZBRRTOVSA-N n-[3-[4-(4-methoxyphenyl)piperazin-1-yl]propyl]-4-[(e)-[4-[(4-methylphenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCNC(=O)C=2C=CC(\C=C\3C(N(CC=4C=CC(C)=CC=4)C4=CC=CC=C4S/3)=O)=CC=2)CC1 VLJWMOHTHSOGFV-LZBRRTOVSA-N 0.000 claims 1
- VRNBNSGAAQOZBE-QCFMCPCVSA-N n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-4-[(e)-[4-[(2-fluorophenyl)methyl]-3-oxo-1,4-benzothiazin-2-ylidene]methyl]benzamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C=CC(\C=C\3C(N(CC=4C(=CC=CC=4)F)C4=CC=CC=C4S/3)=O)=CC=2)CC1 VRNBNSGAAQOZBE-QCFMCPCVSA-N 0.000 claims 1
- UBHIHJMGQIFGOI-XBQJKBNESA-N n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-4-[(e)-[4-[(3-methylphenyl)methyl]-3-oxo-1,4-benzoxazin-2-ylidene]methyl]benzamide Chemical compound CC1=CC=CC(CN2C3=CC=CC=C3OC(/C2=O)=C/C=2C=CC(=CC=2)C(=O)NCCCN2CCN(CC2)C=2C(=CC=C(Cl)C=2)C)=C1 UBHIHJMGQIFGOI-XBQJKBNESA-N 0.000 claims 1
- VZAAGSJCIMQODR-UHFFFAOYSA-N n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-6-oxo-5,6a,7,8,9,10-hexahydropyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C=C3NC(=O)C4CCCCN4C3=CC=2)CC1 VZAAGSJCIMQODR-UHFFFAOYSA-N 0.000 claims 1
- OOPPPLRQMWGFHP-UHFFFAOYSA-N n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-9-oxo-10h-phenanthrene-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C=C3C(C4=CC=CC=C4C(=O)C3)=CC=2)CC1 OOPPPLRQMWGFHP-UHFFFAOYSA-N 0.000 claims 1
- SOGJHPXOGNUDHD-UHFFFAOYSA-N n-[3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]propyl]-9-oxo-5,6,7,8,8a,10-hexahydro-4bh-phenanthrene-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C=C3CC(=O)C4CCCCC4C3=CC=2)CC1 SOGJHPXOGNUDHD-UHFFFAOYSA-N 0.000 claims 1
- KGEHIJRLAGFUEO-UHFFFAOYSA-N n-[3-[4-[5-chloro-2-(trifluoromethyl)phenyl]piperazin-1-yl]propyl]-5-methyl-6-oxo-7,8,9,10-tetrahydro-6ah-pyrido[1,2-a]quinoxaline-3-carboxamide Chemical compound C1=C2N(C)C(=O)C3CCCCN3C2=CC=C1C(=O)NCCCN(CC1)CCN1C1=CC(Cl)=CC=C1C(F)(F)F KGEHIJRLAGFUEO-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000017692 primary erythermalgia Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- CGJMVNVWQHPASW-UHFFFAOYSA-N quinoxaline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CN=C21 CGJMVNVWQHPASW-UHFFFAOYSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CI=*N=C(*)C(*)=IC Chemical compound CI=*N=C(*)C(*)=IC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
Abstract
1. Соединение, имеющее структурную формулу (I):или его соль, сольват или физиологически функциональное производное;где:n равно 1, 2 или 3;m равно 0 или 1;А представляет собой С, N, O, S, NR, C=CR(E- и Z-изомеры), C=NR(E- и Z-изомеры) или C(RR), CR=CR-CR'R' (E- и Z-изомеры) или CR=CR-NR' (E- и Z-изомеры);когда n равно 2 или 3, любой из двух соседних A вместе с другими атомами образует одно или два кольца, где каждое из колец является, необязательно, замещенным;B представляет собой C, N, O, S, NRили C(RR);J, K, L и M независимо представляют собой N или CR;Y представляет собой O, S, NRили C(RR);каждый из R, R, R, R, R, Rи Rнезависимо представляет собой водород, галоген, ацил, замещенный ацил, алкоксикарбонил, замещенный алкоксикарбонил, арилоксикарбонил, замещенный арилоксикарбонил, -CONRR, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил;Rи Rнезависимо представляют собой водород, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил; или, альтернативно, Rи Rвместе с атомом азота, к которому они присоединены, образуют 4-, 5-, 6- или 7-членное циклогетероалкильное кольцо, при условии, что Rи Rотличны от водорода.2. Соединение по п.1, имеющее структурную формулу (IV):или его соль, сольват или физиологически функциональное производное;где:Aи A' являются независимо выбранными из NR, C=CR(E- и Z-изомеры), C=NR(E- и Z-изомеры) или C(RR); или, альтернативно, Aи A' вместе с другими атомами образуют кольцо, которое является, необязатель�
Claims (29)
1. Соединение, имеющее структурную формулу (I):
или его соль, сольват или физиологически функциональное производное;
где:
n равно 1, 2 или 3;
m равно 0 или 1;
А представляет собой С, N, O, S, NR1, C=CR1 (E- и Z-изомеры), C=NR1 (E- и Z-изомеры) или C(R1R2), CR1=CR2-CR1'R2' (E- и Z-изомеры) или CR1=CR2-NR1' (E- и Z-изомеры);
когда n равно 2 или 3, любой из двух соседних A вместе с другими атомами образует одно или два кольца, где каждое из колец является, необязательно, замещенным;
B представляет собой C, N, O, S, NR3 или C(R3R4);
J, K, L и M независимо представляют собой N или CR5;
Y представляет собой O, S, NR6 или C(R6R7);
каждый из R1, R2, R3, R4, R5, R6 и R7 независимо представляет собой водород, галоген, ацил, замещенный ацил, алкоксикарбонил, замещенный алкоксикарбонил, арилоксикарбонил, замещенный арилоксикарбонил, -CONR8R9, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил;
R8 и R9 независимо представляют собой водород, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил; или, альтернативно, R8 и R9 вместе с атомом азота, к которому они присоединены, образуют 4-, 5-, 6- или 7-членное циклогетероалкильное кольцо, при условии, что R8 и R9 отличны от водорода.
2. Соединение по п.1, имеющее структурную формулу (IV):
или его соль, сольват или физиологически функциональное производное;
где:
A4 и A4' являются независимо выбранными из NR1, C=CR1 (E- и Z-изомеры), C=NR1 (E- и Z-изомеры) или C(R1R2); или, альтернативно, A4 и A4' вместе с другими атомами образуют кольцо, которое является, необязательно, замещенным; и связь между A4 и A4' может быть одинарной или двойной.
3. Соединение по п.2, имеющее структурную формулу (IVd):
или его соль, сольват или физиологически функциональное производное;
где:
A4 и X4 независимо представляют собой CR11R12 или NR11;
C=X4 может быть либо Е-, либо Z-изомером; и
R11 и R12 независимо представляют собой водород, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил.
4. Соединение по п.3, выбранное из группы, состоящей из:
5. Соединение по п.2, имеющее структурную формулу (IVb):
или его соль, сольват или физиологически функциональное производное;
где: кольцо R представляет собой арил, замещенный арил, циклоалкил, замещенный циклоалкил, циклогетероалкил, замещенный циклогетероалкил, гетероарил или замещенное гетероарильное кольцо.
6. Соединение по п.5, имеющее структурную формулу (IVb.2):
или его соль, сольват или физиологически функциональное производное;
где: A4-U1, U1-U2, U2-U3, U3-X3, A4'-X3, A4-A4' независимо представляют собой одинарную или двойную связь;
U1, U2, U3 и X3 независимо представляют собой S, O, N, N(R20), C(R20) или C(R20R21);
A4 и A4' независимо представляют собой N, C или CR22;
R20, R21 и R22 независимо представляют собой водород, галоген, ацил, замещенный ацил, алкоксикарбонил, замещенный алкоксикарбонил, арилоксикарбонил, замещенный арилоксикарбонил, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил.
7. Соединение по п.6, выбранное из группы, состоящей из:
9. Соединение по п.8, выбранное из группы, состоящей из:
11. Соединение по п.10, выбранное из группы, состоящей из:
12. Соединение по п.1, имеющее структурную формулу (V):
или его соль, сольват или физиологически функциональное производное;
где: A4-X4, A5-X5 независимо представляют собой NR1, C=CR1 (E- и Z-изомеры), C=NR1 или C(R1R2);
Z3 и Z4 независимо представляют собой O, S, NR3 или C(R3R4); или, альтернативно, Z3-A4-X4 или X4-A4-A5-X5 вместе с другими атомами образуют шести- или семичленное кольцо, которое, необязательно, является замещенным.
13. Соединение по п.12, выбранное из группы, состоящей из:
14. Соединение по п.12, имеющее структурную формулу (Vd):
или его соль, сольват или физиологически функциональное производное;
где: Z3-U4, U4-U5, U5-U6, U6-X4, A4-X4, Z3-A4 независимо представляют собой одинарную или двойную связь;
U4, U5, U6 и X4 независимо представляют собой S, O, Ν, N(R19), C(R19), C(R19R20);
Z3 и A4 независимо представляют собой N, C или CR21;
R19, R20 и R21 независимо представляют собой водород, галоген, ацил, замещенный ацил, алкоксикарбонил, замещенный алкоксикарбонил, арилоксикарбонил, замещенный арилоксикарбонил, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил.
15. Соединение по п.14, выбранное из группы, состоящей из:
17. Соединение по п.16, выбранное из группы, включающей в себя:
18. Соединение по п.1, имеющее структурную формулу (VI):
или его соль, сольват или физиологически функциональное производное;
где: A61, A62 и A63 независимо представляют собой C, N, O, S, NR1, C=CR1 (E- и Z-изомеры), C=NR1 (E- и Z-изомеры) или C(R1R2);
A61-A62 и A62-A63 независимо представляют собой одинарную или двойную связь.
20. Соединение по п.19, имеющее структурную формулу (VIa.11):
или его соль, сольват или физиологически функциональное производное;
где: nn представляет собой целое число от 0 до 4;
A66 представляет собой NR73 или CR73R74;
R72, R73 и R74 независимо представляют собой водород, галоген, цианогруппу, нитрогруппу, аминогруппу, замещенную аминогруппу, сульфонил, замещенный сульфонил, ацил, замещенный ацил, алкоксикарбонил, замещенный алкоксикарбонил, арилоксикарбонил, замещенный арилоксикарбонил, -CONR75R76, S(O)2NR75R76, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил;
R75 и R76 независимо представляют собой водород, алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, гетероалкил или замещенный гетероалкил или, альтернативно, R75 и R76 вместе с атомом азота, к которому они присоединены, образуют 4-, 5-, 6- или 7-членное циклогетероалкильное кольцо.
21. Соединение по п.20, выбранное из группы, состоящей из:
22. Фармацевтическая композиция, содержащая терапевтически эффективное количество соединения или его соли, сольвата или физиологически функционального производного; и, по меньшей мере, один фармацевтически приемлемый носитель; где указанное соединение представляет собой соединение по любому из пп.1-21.
23. Способ лечения заболевания, расстройства, симптома или состояния, связанного с аномальной активностью TrkA у пациента, включающий введение пациенту терапевтически эффективного количества соединения по любому из пп.1-21 или его соли, сольвата или физиологически функционального производного.
24. Фармацевтическая композиция по п.22, которая включена в пероральную дозу или в инъекцию, или в трансдермальный пластырь, или в имплантируемый препарат-депо.
25. Фармацевтическая композиция, содержащая: (а) соединение по любому из пп.1-21 или его соль, сольват или физиологически функциональное производное и (b), по меньшей мере, одно дополнительное активное вещество, выбранное из группы, состоящей из ингибитора протеинкиназы A (PKA), ингибитора сигнальной системы cAMP, нестероидного противовоспалительного лекарственного средства, ингибитора синтеза простагландинов, местного анестетика, антиконвульсанта, антидепрессанта, агониста опиоидных рецепторов, нейролептика, агониста рецепторов GABAA, анальгетика или противоопухолевого средства, действующего по механизму, отличному от агониста TrkA, бензодиазепина, барбитурата, нейростероида и ингаляционного анестетика, анестетика, противоракового лекарственного средства, модулятора рецептора mGluR5 и их комбинации.
26. Способ лечения заболевания, расстройства, симптома или состояния, связанного с аномальной активностью TrkA у пациента, включающий совместное введение пациенту терапевтически эффективного количества
(a) соединения по любому из пп.1-21 или его соли, сольвата или физиологически функционального производного в комбинации с
(b), по меньшей мере, одним дополнительным активным веществом, выбранным из группы, состоящей из ингибитора протеинкиназы A (PKA), ингибитора сигнальной системы cAMP, нестероидного противовоспалительного лекарственного средства, ингибитора синтеза простагландинов, местного анестетика, антиконвульсанта, антидепрессанта, агониста опиоидных рецепторов, нейролептика, агониста рецепторов GABAA, анальгетика или противоопухолевого средства, действующего по механизму, отличному от агониста TrkA, бензодиазепина, барбитурата, нейростероида и ингаляционного анестетика, анестетика, противоракового лекарственного средства, модулятора рецептора mGluR5 и их комбинации.
27. Способ по п.23 или 26, где заболевание, расстройство, симптом или состояние являются выбранными из группы, состоящей из: острой боли, хронической боли, воспалительной боли, невропатической боли, тонической боли, постоянной боли, послеоперационной боли, боли, вызванной химическими реагентами, боли, вызванной химиотерапевтическими средствами, боли при раке, боли, вызванной лекарственными средствами, костной боли, боли, связанной с гипералгезией, индуцированной алкоголем, тревожностью, спазмами скелетных мышц, конвульсивными судорогами, эпилепсией, рестенозом, атеросклерозом, псориазом, тромбозом, ожогом, расстройствами послетравматического стресса, сердечными расстройствами, курением, воспалением и иммунологически опосредуемыми расстройствами (включая микробную инфекцию и трансплантацию органов), раком (включая рак молочной железы, головы и шеи, предстательной железы и легкого), заболеваниями, расстройствами или повреждениями, относящимися к дисмиелинизации или демиелинизации, или их комбинации.
28. Способ по п.23 или 26, где заболевание, расстройство или симптом, или состояние являются обусловленными или связанными с каузалгией, диабетом, коллагеновым сосудистым заболеванием, невралгией тройничного нерва, повреждением спинного мозга, повреждением ствола мозга, таламическим болевым синдромом, комплексным региональным болевым синдромом типа I/симпатической рефлекторной дистрофией, синдромом Фабри, невропатией мелких волокон, раком, химиотерапией рака, хроническим алкоголизмом, инсультом, абсцессом, демиелинизирущим заболеванием, вирусной инфекцией, антивирусной терапией, СПИД, терапией СПИД, ожогом, солнечным ожогом, артритом, колитом, кардитом, дерматитом, невритом, мукозитом, уретритом, циститом, гастритом, пневмонией, травмой, хирургической операцией, ампутацией, токсином, дезадаптирующим употреблением психоактивных веществ, зависимостью от психоактивных веществ, потреблением алкоголя или злоупотреблением алкоголем, потреблением психоактивных веществ или злоупотреблением психоактивными веществами, потреблением наркотиков или злоупотреблением наркотиками, эффектом, связанный с наркотиками, метастазированием, фибромиалгией, синдромом раздраженной толстой киски, височно-нижнечелюстным расстройством, воспалением, иммунной аномалией и их комбинацией.
29. Набор-комплект соединения по любому из пп.1-21 или фармацевтической композиции по любому из пп.22, 24 или 25.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12082708P | 2008-12-08 | 2008-12-08 | |
US61/120,827 | 2008-12-08 | ||
PCT/US2009/067197 WO2010077680A2 (en) | 2008-12-08 | 2009-12-08 | Compositions of protein receptor tyrosine kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016116516A Division RU2016116516A (ru) | 2008-12-08 | 2009-12-08 | Композиции ингибиторов тирозинкиназных рецепторов белков |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011128013A true RU2011128013A (ru) | 2013-01-20 |
RU2586212C2 RU2586212C2 (ru) | 2016-06-10 |
Family
ID=42310499
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011128013/04A RU2586212C2 (ru) | 2008-12-08 | 2009-12-08 | Композиции ингибиторов тирозинкиназных рецепторов белков |
RU2016116516A RU2016116516A (ru) | 2008-12-08 | 2009-12-08 | Композиции ингибиторов тирозинкиназных рецепторов белков |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016116516A RU2016116516A (ru) | 2008-12-08 | 2009-12-08 | Композиции ингибиторов тирозинкиназных рецепторов белков |
Country Status (12)
Country | Link |
---|---|
US (4) | US9040508B2 (ru) |
EP (1) | EP2376495A4 (ru) |
JP (4) | JP5752601B2 (ru) |
KR (1) | KR101805754B1 (ru) |
CN (2) | CN102292338B (ru) |
AU (2) | AU2016200153A1 (ru) |
BR (1) | BRPI0922224A2 (ru) |
CA (1) | CA2746220A1 (ru) |
MX (1) | MX2011006108A (ru) |
NZ (1) | NZ593937A (ru) |
RU (2) | RU2586212C2 (ru) |
WO (1) | WO2010077680A2 (ru) |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2567283T3 (es) | 2008-06-03 | 2016-04-21 | Intermune, Inc. | Compuestos y métodos para tratar trastornos inflamatorios y fibróticos |
RU2586212C2 (ru) | 2008-12-08 | 2016-06-10 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
CA2774715C (en) | 2009-07-27 | 2018-04-03 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CN103096977B (zh) | 2010-07-02 | 2017-02-15 | 吉利德科学公司 | 作为离子通道调节剂的稠杂环化合物 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
AU2012207393A1 (en) * | 2011-01-20 | 2013-08-08 | The Board Of Trustees Of The Leland Stanford Junior University | Quinazolinone inhibitors of dynein |
US9376406B2 (en) * | 2011-03-03 | 2016-06-28 | Indiana University Research And Technology Corporation | uPAR-uPA interaction inhibitors and methods for treating cancer |
CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
SG10201913053QA (en) | 2011-05-13 | 2020-03-30 | Array Biopharma Inc | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
EP2714048A4 (en) * | 2011-05-27 | 2014-11-05 | Univ Temple | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO [B] [1,4] THIAZIN-3 (4H) -ONES, DERIVED THEREFROM, AND THEIR THERAPEUTIC USES |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (ru) | 2011-07-01 | 2018-04-28 | ||
US9102673B2 (en) | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
CA2854936A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2858501A4 (en) | 2012-05-22 | 2015-12-09 | Merck Sharp & Dohme | TRK-A KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
AR091424A1 (es) | 2012-06-13 | 2015-02-04 | Incyte Corp | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) |
CN104797267A (zh) | 2012-06-26 | 2015-07-22 | 德玛医药 | 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
CN104903310B (zh) | 2012-11-13 | 2018-08-14 | 阵列生物制药公司 | 可用于治疗疼痛的双环脲、硫脲、胍及氰基胍化合物 |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
JP6316834B2 (ja) | 2012-11-13 | 2018-04-25 | アレイ バイオファーマ、インコーポレイテッド | Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物 |
US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
JP2015537028A (ja) * | 2012-11-16 | 2015-12-24 | アラーガン、インコーポレイテッドAllergan,Incorporated | 皮膚修復のための組成物および方法 |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
WO2014108808A2 (en) * | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
RU2519546C1 (ru) * | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
US8999992B2 (en) * | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
JP6373978B2 (ja) | 2013-05-27 | 2018-08-15 | ノバルティス アーゲー | イミダゾピロリジノン誘導体および疾患の処置におけるその使用 |
WO2014191906A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
WO2014191911A1 (en) | 2013-05-28 | 2014-12-04 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
CN106029077A (zh) * | 2013-08-01 | 2016-10-12 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
TWI657085B (zh) | 2013-10-04 | 2019-04-21 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2931249A1 (en) | 2013-11-21 | 2015-05-28 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
NO2699580T3 (ru) | 2014-01-24 | 2018-02-24 | ||
EP3527569B1 (en) | 2014-02-03 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye |
US9346788B2 (en) * | 2014-02-05 | 2016-05-24 | VM Oncology, LLC | TrkA receptor tyrosine kinase antagonists and uses thereof |
ES2913486T3 (es) | 2014-03-19 | 2022-06-02 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
EP3131891A1 (en) | 2014-04-15 | 2017-02-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
EP3154959B1 (en) | 2014-05-15 | 2019-07-10 | Array Biopharma, Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
EP3193874A4 (en) | 2014-09-17 | 2018-04-25 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
TW201632520A (zh) | 2014-11-25 | 2016-09-16 | 拜耳製藥股份有限公司 | 經取代之吡啶並苯並二氮呯酮衍生物及其用途 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
MX2017010673A (es) | 2015-02-20 | 2018-03-21 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
WO2017023994A1 (en) | 2015-08-06 | 2017-02-09 | Yale University | Small molecule based antibody-recruiting compounds for cancer treatment |
CN105198828A (zh) * | 2015-08-26 | 2015-12-30 | 中国药科大学 | 杂环蒽酮类组蛋白甲基转移酶抑制剂及其医药用途 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017161235A1 (en) | 2016-03-18 | 2017-09-21 | Purdue Pharma L. P. | Process for preparing substituted 9,10-dioxo-9,10-dioxo-9,10-dihydroanthrecenes and 6h-anthra(1,9-cd)isoxazol-6-ones |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11034702B2 (en) * | 2016-12-06 | 2021-06-15 | Valorbec, Société en commandite | Thienoisoquinolines and their derivatives for the treatment of cancer |
WO2018196662A1 (zh) * | 2017-04-28 | 2018-11-01 | 四川科伦博泰生物医药股份有限公司 | 包含苯并二氮䓬类化合物的注射用组合物及其制备方法 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MX2020000887A (es) | 2017-07-24 | 2020-07-22 | Vitae Pharmaceuticals Llc | Inhibidores de ror?. |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
JP7065951B2 (ja) | 2017-09-22 | 2022-05-12 | ジュビラント エピパッド エルエルシー | Pad阻害剤としての複素環式化合物 |
CA3078555A1 (en) | 2017-10-06 | 2019-04-11 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
MX2020005363A (es) | 2017-11-24 | 2020-10-01 | Jubilant Episcribe Llc | Compuestos heterociclicos como inhibidores de prmt5. |
JP7335893B2 (ja) | 2017-12-22 | 2023-08-30 | ラヴェンナ ファーマシューティカルズ,インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのクロメノピリジン誘導体 |
CA3087080A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Degraders of egfr and methods of use thereof |
JP2021514400A (ja) * | 2018-02-20 | 2021-06-10 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfrの阻害剤およびその使用法 |
CA3088561A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Degraders of egfr and methods of use thereof |
CA3087716A1 (en) | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
WO2019164949A1 (en) * | 2018-02-20 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |
AU2019225799A1 (en) * | 2018-02-20 | 2020-07-09 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical combinations of EGFR inhibitors and methods of use thereof |
MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
MA52494A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
WO2019243823A1 (en) * | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Azaheterocyclic small molecule modulators of human sting |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
JOP20220087A1 (ar) | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
WO2021119525A1 (en) * | 2019-12-11 | 2021-06-17 | Tiaki Therapeutics Inc. | Shp1 and shp2 inhibitors and their methods of use |
WO2022044024A1 (en) * | 2020-08-31 | 2022-03-03 | Ramot At Tel-Aviv University Ltd. | Small molecule modulators of gsk-3 activity |
CN114470189B (zh) * | 2020-11-12 | 2024-01-16 | 达石药业(广东)有限公司 | Ngf抗体在cipn性疼痛中的应用 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
WO2023011608A1 (zh) * | 2021-08-05 | 2023-02-09 | 上海枢境生物科技有限公司 | 含三并环类衍生物调节剂、其制备方法和应用 |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2024026076A2 (en) * | 2022-07-29 | 2024-02-01 | Septerna, Inc. | Substituted 3,4-dihydroquinolinone inhibitors of tshr |
US11773092B1 (en) | 2023-03-27 | 2023-10-03 | King Faisal University | Pyrido[3,4-b]indol-1-one compounds as antibacterial agents |
CN116854689B (zh) * | 2023-09-04 | 2023-11-17 | 中国药科大学 | 一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1181318A (en) * | 1914-02-12 | 1916-05-02 | Kellogg Mfg Co | Pump. |
GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
RU2065438C1 (ru) * | 1993-12-22 | 1996-08-20 | Институт химии природного органического сырья СО РАН | Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она |
US6635626B1 (en) * | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
US6476032B2 (en) | 1998-12-17 | 2002-11-05 | Wyeth | 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives |
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
CZ20014244A3 (cs) | 1999-06-03 | 2002-07-17 | Knoll Gmbh | Benzotiazinonové a benzoxazinonové sloučeniny |
FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
DE60215682T2 (de) * | 2001-09-27 | 2007-09-06 | Smithkline Beecham Corp. | AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ |
KR20030095729A (ko) | 2002-06-14 | 2003-12-24 | 크리스탈지노믹스(주) | 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5H-티아졸로[3,2-a]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1B 활성 억제용 약학 조성물 |
PL211654B1 (pl) | 2002-10-08 | 2012-06-29 | Rinat Neuroscience Corp | Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
SI2270048T1 (sl) | 2002-12-24 | 2016-01-29 | Rinat Neuroscience Corp. | Protitelesa proti NGF-ju in postopki uporabe le-teh |
IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
CN102408483B (zh) | 2003-07-15 | 2016-06-08 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
US8362264B2 (en) | 2003-08-22 | 2013-01-29 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with Trp-p8 expression |
WO2008021463A2 (en) | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
WO2006036936A2 (en) | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
US7820668B2 (en) * | 2005-01-19 | 2010-10-26 | Eisai Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
FR2881138B1 (fr) | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
US8498961B2 (en) * | 2006-07-13 | 2013-07-30 | International Business Machines Corporation | On-demand replication in a content management system |
WO2008053863A1 (fr) | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one |
EP2114948B1 (en) * | 2006-12-28 | 2014-06-25 | AbbVie Inc. | Inhibitors of poly(adp-ribose)polymerase |
US20100136116A1 (en) | 2007-08-17 | 2010-06-03 | Hetero Drugs Limited | Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
RU2586212C2 (ru) | 2008-12-08 | 2016-06-10 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
US8853235B2 (en) | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
CN102947308A (zh) | 2010-06-23 | 2013-02-27 | Osi药物有限责任公司 | Osi-906的多晶型物 |
SG10201600179RA (en) | 2011-01-10 | 2016-02-26 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9376406B2 (en) | 2011-03-03 | 2016-06-28 | Indiana University Research And Technology Corporation | uPAR-uPA interaction inhibitors and methods for treating cancer |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
EP3193874A4 (en) | 2014-09-17 | 2018-04-25 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
-
2009
- 2009-12-08 RU RU2011128013/04A patent/RU2586212C2/ru not_active IP Right Cessation
- 2009-12-08 NZ NZ593937A patent/NZ593937A/en not_active IP Right Cessation
- 2009-12-08 CN CN200980150091.4A patent/CN102292338B/zh not_active Expired - Fee Related
- 2009-12-08 KR KR1020117015933A patent/KR101805754B1/ko active IP Right Grant
- 2009-12-08 WO PCT/US2009/067197 patent/WO2010077680A2/en active Application Filing
- 2009-12-08 EP EP09836726A patent/EP2376495A4/en active Pending
- 2009-12-08 BR BRPI0922224A patent/BRPI0922224A2/pt not_active IP Right Cessation
- 2009-12-08 JP JP2011540836A patent/JP5752601B2/ja not_active Expired - Fee Related
- 2009-12-08 CA CA2746220A patent/CA2746220A1/en not_active Abandoned
- 2009-12-08 CN CN201610710315.4A patent/CN106336400A/zh active Pending
- 2009-12-08 US US13/133,565 patent/US9040508B2/en active Active
- 2009-12-08 RU RU2016116516A patent/RU2016116516A/ru unknown
- 2009-12-08 MX MX2011006108A patent/MX2011006108A/es unknown
-
2014
- 2014-04-18 US US14/256,094 patent/US8809530B1/en active Active
- 2014-08-22 JP JP2014169006A patent/JP2014218524A/ja not_active Withdrawn
-
2015
- 2015-04-14 US US14/685,806 patent/US9738659B2/en active Active
-
2016
- 2016-01-11 AU AU2016200153A patent/AU2016200153A1/en not_active Abandoned
- 2016-07-08 JP JP2016135647A patent/JP2016180005A/ja not_active Withdrawn
-
2017
- 2017-08-14 US US15/676,039 patent/US10421763B2/en active Active
- 2017-10-11 JP JP2017197589A patent/JP2018002741A/ja active Pending
- 2017-10-18 AU AU2017248456A patent/AU2017248456A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011128013A (ru) | Композиции ингибиторов тирозинкиназных рецепторов белков | |
JP2012511054A5 (ru) | ||
JP5128019B1 (ja) | オキサジン誘導体および神経障害の処置におけるその使用 | |
JP6600388B2 (ja) | P2x4受容体拮抗剤 | |
KR102092147B1 (ko) | P2x4 수용체 길항제 | |
AU2010274913B2 (en) | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | |
WO2015005468A1 (ja) | P2x4受容体拮抗剤 | |
ES2222401T3 (es) | Derivados de piperazina, su preparacion y su uso para el tratamiento de trastornos del sistema nervioso central. | |
JPWO2008007664A1 (ja) | 二環性複素環化合物およびその用途 | |
AU630904B2 (en) | Benzoxazepine derivative | |
WO1997017970A1 (fr) | Inhibiteurs de la neurotoxicite de l'acide kainique et derives de la pyridothiazine | |
PL201176B1 (pl) | Metanosulfonian 8-{4-[3-(5-fluoro-1H-indol-3-ilo)-propylo]-piperazyno-1-ylo}-2-metylo-4H-benzo[1,4]ksazyn-3-onu o powinowactwie do receptora dopaminy D2 i miejsca ponownego wychwytu serotoniny oraz kompozycja farmaceutyczna | |
AU2009333537B8 (en) | Compositions of protein receptor tyrosine kinase inhibitors | |
JPH09151186A (ja) | 縮合トリアゾール化合物 | |
JPH11310532A (ja) | 熱産生促進剤 | |
JP2020180059A (ja) | バソプレシン受容体拮抗剤 | |
JP2002138053A (ja) | 中枢神経系疾患予防・治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant | ||
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181209 |